Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve

January 28, 2024 updated by: Xiaomei Shao

Efficacy of Thumb-tack Needle Treatment for Diminished Ovarian Reserve: Study Protocol for a Randomized Controlled Trial

Diminished Ovarian Reserve (DOR) is characterized as an important cause of infertility. Acupuncture has been extensively used to treat female infertility. This study was conducted to investigate the efficacy of thumb-tack needle,as a new special type of acupuncture and long-lasting treatment modality,in the treatment of DOR.

Study Overview

Detailed Description

There will be a multi-center, randomized, sham-controlled trial. 106 patients will be randomly assigned into thumb-tack needle acupuncture or sham-acupuncture in 1:1 ratio. All the patents will achieve 12 sessions of verum or sham treatments in 20 weeks(12 weeks for treatment and 8 weeks for follow-up). Patients, outcome assessors and statisticians are masked from group assignment. The study is aim to evaluate the efficacy of thumb-tack needle for DOR.

Study Type

Interventional

Enrollment (Estimated)

106

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Zhejiang
      • Hangzhou, Zhejiang, China
        • Recruiting
        • the Third Affiliated Hospital of Zhejiang Chinese Medical University
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • 18 years old ≤ age < 40 years old, female;
  • Clinical diagnosis of Diminished Ovarian Reserve: meet both items in twice tests with an interval of at least 4 weeks(tested between 2rd to 4th day of menstrual cycle):

    1. 10 IU/L < FSH < 20 IU/L,
    2. Anti-Müllerian hormone(AMH) < 1.1ng/mL.
  • without any mind disease, willing to participate in the study and sign the informed consent.
  • without any other treatment.

Exclusion Criteria:

  • Low or no response to exogenous gonadotropins, or with congenital anomalies in the development of the reproductive tract;
  • Pregnant or breastfeeding;
  • Abnormal body temperatures at the moment;
  • Psychopath, alcoholic, Patient with severe depression, history of substance abuse and severe primary diseases of cardiovascular, liver, kidney and hematopoietic system;
  • Currently enrolled in other clinical trials or refuse to cooperate with the study protocol.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Thumb-tack needle acupuncture
53 Patients in this group will achieve 24 sessions treatment of thumb-tack needle in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
Sterilizing skin and avoiding vessels, the thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The thumb-tack needle will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.
Gynecological health care guidance will be provided as patients needed.
Sham Comparator: Sham acupuncture group
A sham thumb-tack needle, which has no difference in appearance with the verum thumb-tack needle but is lack of needle, are used for 53 patient in this group. 24 sessions of treatment will be performed in 12 consecutive weeks. Treatment will be operated by trained acupuncturists.
Gynecological health care guidance will be provided as patients needed.
Sterilizing skin and avoiding vessels, the sham thumb-tack needle are directly stock to the surface of acupoints by a band-aid, kneading and pressing for 5 minutes. The sham device will be embedded in the skin and keep staying for 72 hours. Patients will be taught to press them 3 to 4 times per day. As tolerated by them, each pressing will lasts 1 minutes with an interval of about 4 hours.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
changes of serum follicle-stimulating hormone (FSH) level
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
The increasing of serum follicle-stimulating hormone(FSH) is one of the main symptoms of Diminished Ovarian Reserve. The normal value of FSH is 1.37-9.9 U/L in follicular phase, and higher the FSH value, the worse ovarian function. Patients in this study will be asked to take the serum FSH text between day2 to day4 of menstrual period in whole observation. Patients with amenorrhea take every 28 days as a supposed menstrual cycle instead.
baseline,week 4, week 12,week 20(week 8 in follow-up)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
changes of 1.Serum Anti-Müllerian Hormone (AMH) level
Time Frame: baseline,week 12, week 20(week 8 in follow-up)
AMH is another recommend index to measure ovarian function. Compared to FSH, Anti-Müllerian Hormone has less fluctuation and more accuracy. The normal value of serum AMH is 2-6.8ng/ml in follicular phase, and lower the value, the worse condition.
baseline,week 12, week 20(week 8 in follow-up)
temperature of sensitized acupoint
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
"Acupoint sensitization" suggests that there are specific changes of biological characteristics on the body surface or acupuncture points in a pathological state. Acupoints associated with the disease may manifest as sensitivity to pain and heat. Infrared thermography (IRT) will be used to measured the temperature of the DOR-related acupoints.
baseline,week 4, week 12,week 20(week 8 in follow-up)
pain threshold of sensitized acupoint
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
Pain threshold of DOR-related acupoints will be tested by pressure pain threshold gauge (PTG).
baseline,week 4, week 12,week 20(week 8 in follow-up)
the modified Kupperman Index(KI)
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
The modified Kupperman Index (KI) is widely used for female self-evaluation of the severity of menopausal symptoms in clinical practice. It values 13 items of menopausal symptoms on a scale of 0 to 3. The final score of KI is the sum of each score multiplied with the base score respectively, ranging from 0-63. The final KI score is less than 6 means normal, between 6 to 15 are classified as mild, 16 to 30 as moderate, and greater than 30 as severe.
baseline,week 4, week 12,week 20(week 8 in follow-up)
Self-Rating Anxiety Scale (SAS)
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
According to the frequency of symptom occurrence, the SAS contains 20 items reflecting subjective feelings of anxiety, and each item is rated on a four-point scale of 1 to 4, including 15 positive and 5 negative items. 1 means never, 2 is for sometimes, 3 is for frequently, 4 is always. Positive items are rating from 1-4, while negative items is from 4 to 1. Once the evaluation is complete, the scores for each of the 20 items are added together as score X. Score X will multiply by 1.25 and then round to the nearest whole number to obtain a standardized score Y, which is the final result of SAS. According to the Chinese normative results, the cut-off value of the SAS standardized score is 50, where 50-59 is mild anxiety, 60-69 is moderate anxiety, and 69 or more is severe anxiety.
baseline,week 4, week 12,week 20(week 8 in follow-up)
Self-rating Depression Scale (SDS)
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
The SDS also contains 20 items reflecting subjective feelings of depression, with 10 positive and 10 negative ratings. 1 means never, 2 is for sometimes, 3 is for frequently, 4 is always. Positive items are rating from 1-4, while negative items is from 4 to 1. Once the evaluation is complete, the scores for each of the 20 items are added together as score X. Score X will multiply by 1.25 and then round to the nearest whole number to obtain a standardized score Y, which is the final result of SDS.The cut-off value of SDS standardized score is 53, where 53 to 62 is considered as mild depression, 63 to 72 is moderate depression, and 72 or more is severe depression.
baseline,week 4, week 12,week 20(week 8 in follow-up)
Psychological constitution of traditional Chinese medicine(TCM)
Time Frame: baseline,week 4, week 12,week 20(week 8 in follow-up)
The TCM psychological constitution scale is compiled by Professor Wang Qi of Beijing University of Chinese Medicine, which is widely used in clinical practice. There are 9 items and 66 small items in the TCM constitution scale, and it requires patients fill the scale truthfully by themselves according to their real situation in the last year. Nine psychological constitutions will be determined by conversion score: mild constitution, qi deficiency constitution, qi depression constitution, yin deficiency constitution, yang deficiency constitution, blood stasis constitution, special constitution, phlegm-dampness constitution and damp-heat constitution.
baseline,week 4, week 12,week 20(week 8 in follow-up)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Xiaomei Shao, Ph.D, the Third Affiliated Hospital of Zhejiang Chinese Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 3, 2023

Primary Completion (Estimated)

December 30, 2025

Study Completion (Estimated)

December 30, 2025

Study Registration Dates

First Submitted

December 20, 2023

First Submitted That Met QC Criteria

January 16, 2024

First Posted (Actual)

January 25, 2024

Study Record Updates

Last Update Posted (Actual)

January 30, 2024

Last Update Submitted That Met QC Criteria

January 28, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diminished Ovarian Reserve

Clinical Trials on thumb-tack needle

3
Subscribe